X4 Pharmaceuticals (XFOR) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 11, 2026, with virtual participation available to all shareholders of record as of March 13, 2026.

• Shareholders are encouraged to review proxy materials online or request copies before voting.

Voting matters and shareholder proposals

• Election of three Class III directors for terms expiring in 2029: Gary J. Bridger, Françoise De Craecker, and Murray W. Stewart.

• Ratification of PricewaterhouseCoopers LLC as independent auditor for the year ending December 31, 2026.

• Approval of the second amendment and restatement of the 2017 Equity Incentive Plan to increase shares available.

• Advisory vote on executive compensation for named executive officers.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and compensation matters.